Author:
Raines Kimberly,Agarwal Payal,Augustijns Patrick,Alayoubi Alaadin,Attia Lucas,Bauer-Brandl Annette,Brandl Martin,Chatterjee Parnali,Chen Hansong,Yu Yuly Chiang,Coutant Carrie,Coutinho Ana Luisa,Curran David,Dressman Jennifer,Ericksen Bryan,Falade Leah,Gao Yi,Gao Zongming,Ghosh Debasis,Ghosh Tapash,Govada Anitha,Gray Elizabeth,Guo Ruiqiong,Hammell Dana,Hermans Andre,Jaini Rohit,Li Hanlin,Mandula Haritha,Men Shuaiqian,Milsmann Johanna,Moldthan Huong,Moody Rebecca,Moseson Dana E.,Müllertz Anette,Patel Roshni,Paudel Kalpana,Reppas Christos,Savkur Rajesh,Schaefer Kerstin,Serajuddin Abu,Taylor Lynne S.,Valapil Rutu,Wei Kevin,Weitschies Werner,Yamashita Shinji,Polli James E.
Abstract
AbstractThe in-person workshop “Drug Dissolution in Oral Drug Absorption” was held on May 23–24, 2023, in Baltimore, MD, USA. The workshop was organized into lectures and breakout sessions. Three common topics that were re-visited by various lecturers were amorphous solid dispersions (ASDs), dissolution/permeation interplay, and in vitro methods to predict in vivo biopharmaceutics performance and risk. Topics that repeatedly surfaced across breakout sessions were the following: (1) meaning and assessment of “dissolved drug,” particularly of poorly water soluble drug in colloidal environments (e.g., fed conditions, ASDs); (2) potential limitations of a test that employs sink conditions for a poorly water soluble drug; (3) non-compendial methods (e.g., two-stage or multi-stage method, dissolution/permeation methods); (4) non-compendial conditions (e.g., apex vessels, non-sink conditions); and (5) potential benefit of having both a quality control method for batch release and a biopredictive/biorelevant method for biowaiver or bridging scenarios. An identified obstacle to non-compendial methods is the uncertainty of global regulatory acceptance of such methods.
Publisher
Springer Science and Business Media LLC